CKD–Mineral and Bone Disorder: Disordered Calcium, Phosphate, and Bone Metabolism
CKD–mineral and bone disorder is a systemic complication of chronic kidney disease characterised by abnormal calcium, phosphate, vitamin D, and parathyroid hormone regulation, leading to bone pathology and vascular calcification. It reflects failure of the kidney’s endocrine and regulatory roles rather than a primary bone disease. In CKD-MBD bone fragility can develop even before end-stage kidney disease, fracture risk is high despite normal or increased bone density, and mineral imbalance can contribute to cardiovascular morbidity.
What You Need to Know
Healthy kidneys regulate mineral balance by excreting phosphate, activating vitamin D, and maintaining calcium homeostasis. In chronic kidney disease, declining nephron function disrupts all three of these processes at the same time. Phosphate excretion falls, vitamin D activation becomes impaired, and intestinal calcium absorption decreases, gradually altering the chemical environment of the blood and bone.
These disturbances trigger a coordinated hormonal response involving the parathyroid glands, bone, and kidneys. In CKD:
rising phosphate and falling calcium stimulate parathyroid hormone (PTH) release
reduced vitamin D limits calcium absorption from the gut
PTH increases bone resorption to restore serum calcium
Although this response initially helps stabilise blood calcium levels, it does so at the expense of skeletal integrity. Over time, sustained secondary hyperparathyroidism leads to excessive bone turnover, loss of bone mineral density, and structural weakening, while calcium and phosphate increasingly deposit in blood vessels and soft tissues, contributing to extraskeletal calcification and cardiovascular risk.
Beyond the Basics
Phosphate retention and early mineral imbalance
As glomerular filtration declines in CKD, phosphate excretion becomes progressively inadequate, even before serum phosphate levels rise outside the reference range. This early phosphate retention subtly alters the calcium–phosphate equilibrium and stimulates endocrine responses long before routine blood tests flag an abnormality. Because phosphate is a powerful regulator of parathyroid hormone and vitamin D metabolism, even small increases in phosphate load place significant stress on the bone–mineral axis.
This is why CKD–mineral and bone disorder begins early in the disease course, often before patients develop symptoms or overt biochemical abnormalities. The skeleton and parathyroid glands are already being driven into compensatory activity in response to phosphate retention long before clinicians recognise CKD-MBD.
Impaired vitamin D activation
The kidneys are the primary site where inactive vitamin D is converted into its biologically active form, calcitriol, which is required for efficient intestinal calcium absorption and normal bone mineralisation. As nephron mass declines, this conversion becomes increasingly limited, reducing the amount of active vitamin D available to support calcium homeostasis.
With less active vitamin D, calcium absorption from the gut falls, contributing to declining serum calcium levels. At the same time, vitamin D normally suppresses parathyroid hormone synthesis, so its loss removes an important inhibitory signal. The combined effect of hypocalcaemia and reduced vitamin D feedback strongly promotes parathyroid hormone release.
Secondary hyperparathyroidism and altered bone turnover
Rising phosphate and falling calcium drive persistent stimulation of the parathyroid glands. Initially, this increase in parathyroid hormone helps stabilise serum calcium by increasing bone resorption and enhancing renal calcium reabsorption, but this adaptive response rapidly becomes pathological when kidney function continues to decline.
With chronic stimulation, the parathyroid glands undergo hyperplasia and parathyroid hormone levels remain elevated. Excess hormone activity increases osteoclast-mediated bone resorption while disrupting normal bone remodelling, leading to progressive weakening of skeletal structure and abnormal bone architecture rather than healthy turnover.
Bone pathology and structural weakness
CKD-MBD does not produce a single uniform bone disorder but a spectrum of abnormalities depending on the balance between formation and resorption. In high-turnover disease, excessive resorption produces fragile, poorly mineralised bone that fractures easily, while in low-turnover states, suppressed osteoblast activity limits bone repair and adaptation to mechanical load.
These processes explain why patients with CKD experience high fracture rates, delayed healing, and chronic bone pain even when bone density measurements appear only mildly reduced. In CKD-MBD, bone quality and microarchitecture are compromised as much as mineral content.
Vascular and soft tissue calcification
Disordered calcium and phosphate balance promotes the formation of calcium–phosphate complexes that deposit in blood vessels and soft tissues. Within the vascular wall, smooth muscle cells undergo osteogenic transformation, expressing bone-related proteins and actively participating in pathological calcification.
As calcification progresses, arteries become stiff and lose their ability to accommodate changes in blood flow and pressure. This markedly increases cardiovascular risk, making CKD-MBD a major contributor to cardiovascular mortality rather than a problem confined to the skeleton.
Interaction with acidosis and inflammation
Metabolic acidosis further worsens bone disease by promoting the release of calcium and phosphate from bone as a buffering mechanism. At the same time, chronic inflammation and uraemic toxins impair osteoblast function and collagen synthesis, limiting the skeleton’s ability to repair and maintain itself.
These interacting factors mean that CKD-MBD progresses even when individual abnormalities such as calcium or phosphate appear partially corrected, reflecting a complex, self-reinforcing disorder of mineral metabolism rather than a simple electrolyte imbalance.
Clinical Connections
CKD–mineral and bone disorder often progresses without overt symptoms until structural failure occurs. Bone pain, muscle weakness, fragility fractures or skeletal deformity reflect long-standing disruption of calcium, phosphate and hormonal regulation rather than acute injury. Fractures frequently occur after minimal trauma and may heal poorly because bone turnover is abnormal, with impaired coupling between resorption and formation. These skeletal manifestations often coexist with vascular and soft tissue calcification, indicating that mineral imbalance affects multiple tissues simultaneously.
Several clinical patterns suggest disordered mineral and bone metabolism in CKD:
Fragility fractures or bone pain disproportionate to trauma
Proximal muscle weakness and reduced functional capacity
Poor fracture healing or recurrent fractures despite adequate fixation
Assessment extends beyond serum calcium alone. Elevated phosphate, rising parathyroid hormone levels, low or inappropriately normal active vitamin D, metabolic acidosis and declining renal function together indicate failure of the renal–bone–endocrine axis. Imaging may show reduced bone density or deformity, but biochemical disturbance often precedes radiographic change. Because bone is sacrificed to maintain extracellular mineral balance, serum calcium may remain within reference ranges despite significant skeletal disease.
Management targets the drivers of metabolic disruption rather than isolated laboratory abnormalities. Reducing phosphate burden limits parathyroid hormone stimulation, restoring vitamin D signalling improves mineral handling and bone formation, and moderating secondary hyperparathyroidism reduces excessive bone resorption. Correction of metabolic acidosis supports osteoblast activity and matrix mineralisation. Addressing these mechanisms together is essential, as calcium supplementation alone does not correct the hormonal and metabolic processes that weaken bone and increase fracture risk in chronic kidney disease.
Concept Check
Why does phosphate retention occur early in chronic kidney disease?
How does impaired vitamin D activation contribute to hypocalcaemia?
Why does secondary hyperparathyroidism weaken bone over time?
How does CKD-MBD increase cardiovascular risk as well as fracture risk?
Why is bone density alone an unreliable indicator of bone strength in CKD?